| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 6.48 | 0.00 (0.00%) | 3.10 - 7.73 | 14.8 thousand (Below Avg) |
Market data as of 4:00PM 05/23/13. Quotes are delayed by at least 15 min.
| Open | -- |
|---|---|
| Previous Close | 6.48 |
| Day's Range | -- - -- |
| Market Cap | 613.3M |
| Avg Volume (10 Day) | 872.9K |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -1.32 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Neutral |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Neutral |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
PR Newswire - Friday 05/17/2013 4:01 PM ET
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of Orexigen Therapeutics, Inc.
Business Wire - Monday 05/13/2013 10:35 AM ET
Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
PR Newswire - Friday 05/10/2013 4:01 PM ET
Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2013
PR Newswire - Wednesday 05/08/2013 4:01 PM ET
Orexigen Therapeutics to Host First Quarter 2013 Financial Results Conference Call and Webcast
PR Newswire - Thursday 05/02/2013 8:30 AM ET
Orexigen Therapeutics Commends the Campaign to End Obesity's Report on Long-term Returns of Obesity Prevention Policies
PR Newswire - Thursday 04/25/2013 4:35 PM ET
| OREX | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 0.00% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.00 | |
| LT Debt/Equity | 0.00 | |
| Earnings Yield | -- | |
| Price/Sales | 178.90 |
| Company | Last | Change |
|---|---|---|
| Simcere Pharmaceutical Group | 9.29 | 0.00% |
| Dynavax Technologies Corp | 2.53 | 0.00% |
| Synergy Pharmaceuticals Inc | 5.11 | 0.00% |
| Sucampo Pharmaceuticals Inc | 8.85 | 0.00% |
| Lannett Company Inc | 12.65 | 0.00% |
Data is delayed by at least 15 min.